AstraZeneca PLC (AZN)
66.30
-0.34
(-0.50%)
USD |
NASDAQ |
Dec 24, 13:00
66.30
0.00 (0.00%)
After-Hours: 13:48
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 205.55B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 2.69% |
| Valuation | |
| PE Ratio | 31.80 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.046 |
| Price to Book Value | 5.048 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.50 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7402 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.87% |
Profile
| A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales. |
| URL | https://www.astrazeneca.com |
| Investor Relations URL | https://www.astrazeneca.com/investor-relations.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Feb. 07, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 09, 2024 |
Ratings
Profile
| A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales. |
| URL | https://www.astrazeneca.com |
| Investor Relations URL | https://www.astrazeneca.com/investor-relations.html |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Feb. 07, 2025 (est.) |
| Last Earnings Release | Nov. 12, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 09, 2024 |